No abstract available
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Arsenic Trioxide
-
Arsenicals / administration & dosage
-
Bone Marrow Neoplasms / diagnosis*
-
Bone Marrow Neoplasms / genetics
-
Bone Marrow Neoplasms / therapy*
-
Brain Neoplasms / diagnosis*
-
Brain Neoplasms / genetics
-
Brain Neoplasms / therapy*
-
Chromosomes, Human, Pair 15
-
Chromosomes, Human, Pair 17
-
Cranial Irradiation
-
Cytarabine / administration & dosage
-
Drug Administration Schedule
-
Female
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Idarubicin / administration & dosage
-
Leukemia, Promyelocytic, Acute / diagnosis*
-
Leukemia, Promyelocytic, Acute / genetics
-
Leukemia, Promyelocytic, Acute / therapy*
-
Magnetic Resonance Imaging
-
Mercaptopurine / administration & dosage
-
Methotrexate / administration & dosage
-
Mutation*
-
Nuclear Proteins / genetics
-
Oxides / administration & dosage
-
Promyelocytic Leukemia Protein
-
Receptors, Retinoic Acid / genetics
-
Recurrence
-
Remission Induction
-
Retinoic Acid Receptor alpha
-
Reverse Transcriptase Polymerase Chain Reaction
-
Transcription Factors / genetics
-
Translocation, Genetic
-
Transplantation, Autologous
-
Treatment Outcome
-
Tretinoin / administration & dosage
-
Tumor Suppressor Proteins / genetics
-
fms-Like Tyrosine Kinase 3 / genetics*
Substances
-
Arsenicals
-
Nuclear Proteins
-
Oxides
-
Promyelocytic Leukemia Protein
-
RARA protein, human
-
Receptors, Retinoic Acid
-
Retinoic Acid Receptor alpha
-
Transcription Factors
-
Tumor Suppressor Proteins
-
Cytarabine
-
PML protein, human
-
Tretinoin
-
Mercaptopurine
-
FLT3 protein, human
-
fms-Like Tyrosine Kinase 3
-
Arsenic Trioxide
-
Methotrexate
-
Idarubicin